R-Health Consult (RHC) is proud to unveil a new report, developed in collaboration with EFPIA, that provides a detailed analysis of the economic and health benefits of investing in five key non-communicable diseases (NCDs). The report focuses on stroke, ischaemic heart disease, type 2 diabetes, chronic obstructive pulmonary disease (COPD), and breast cancer across all 27 European Union Member States. It offers evidence-based recommendations designed to reduce mortality, enhance patient quality of life, and improve return on investment (ROI) for the European economy.
Key Findings:
In 2023, the five major NCDs cost the EU approximately €530 billion, equivalent to 3.13% of the region’s combined annual GDP. Direct healthcare expenditures represent 60.5% of these costs.
Projections indicate that by 2050, the annual number of new NCD cases will reach 7.4 million—a 16% increase from current levels—with deaths rising by 50% compared to 2023.
ROI Analyses and Case Studies:
The report presents ROI analyses from targeted interventions, highlighting the following key points:
Romania – Cardiovascular Care:
Cardiovascular diseases accounted for over 55% of all deaths in Romania in 2020.
Scaling up cardiovascular care could save more than 107,000 lives by 2050.
For every €1 invested, at least €1 is returned to the economy, enabling patients to remain in the workforce.
Portugal – Diabetes Management:
With one of the highest diabetes rates globally at 9.1%, Portugal stands to benefit significantly.
Targeted interventions for diabetes management and enhanced screening are predicted to save approximately 8,700 lives between 2023 and 2050.
Every €1 invested in improved diabetes control could yield a return of €1.4 to the economy.
Scaling up this intervention could avert an estimated 239,000 new cases of diabetes-related complications.
Sweden – Breast Cancer Treatments:
Breast cancer accounted for 7257 new cases and 1456 deaths in 2023.
Projections for 2050 estimate 8,702 new cases (a 20% increase) and 1,887 deaths (a 30% increase) annually.
Comprehensive breast cancer treatment could return up to five times the initial investment directly to the economy.
Areas for action to enable investment
This report underscores the urgent need for a fundamental shift in how health care is perceived and funded across Europe, and makes five recommendations:
Strengthen the role of economic analysis and retrospective research in health budgeting
Improve patient pathways to ensure successful uptake of investment in disease prevention
Strengthen collaboration between health and finance ministries and address governance challenges to align health investments with national priorities
Make a paradigm shift to position health as a strategic investment
Protect and expand investment in health and innovation, aligning funding with strategic priorities to address the investment gap
R-Health Consult remains committed to driving actionable insights and facilitating policy reforms that support sustainable health outcomes and economic growth across Europe. For more detailed information, please refer to the full report. For information on report methodology and detailed results, please refer to the methodology annex.
About us: R-Health Consult is a healthcare consultancy dedicated to delivering strategic insights and innovative policy recommendations. Through robust research and collaborative initiatives, RHC partners with leading organizations to tackle today’s most pressing health challenges.
コメント